DefiniGEN Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 15

Employees

  • Latest Deal Type
  • M&A

DefiniGEN General Information

Description

Developer of highly functional human cell products designed to cure liver disease through highly predictive in vitro modeling. The company's products are stem cell life science products that generate high-functionality cell types, including liver, pancreatic, and lung cells, enabling medical clients to accelerate their research and optimize their workflow.

Contact Information

Website
www.definigen.com
Formerly Known As
Friars 2034
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • The Moneta Building (B280)
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Pixl Bio
Vertical(s)
Artificial Intelligence & Machine Learning, Life Sciences
Corporate Office
  • The Moneta Building (B280)
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DefiniGEN Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 22-Sep-2025 Completed Generating Revenue
10. Later Stage VC (Series B) 26-Sep-2024 Completed Generating Revenue
9. Later Stage VC (Series A) 18-May-2023 Completed Generating Revenue
8. Later Stage VC (Series A) 19-Nov-2020 Completed Generating Revenue
7. Grant 24-Sep-2019 Completed Generating Revenue
6. Later Stage VC 20-Nov-2018 Completed Generating Revenue
5. Later Stage VC 14-Apr-2016 Completed Generating Revenue
4. Grant 01-Jan-2016 Completed Generating Revenue
3. Early Stage VC (Series A) 16-Apr-2014 $3.8M $4.43M Completed Generating Revenue
2. Early Stage VC 15-Nov-2012 $633K $633K Completed Generating Revenue
To view DefiniGEN’s complete valuation and funding history, request access »

DefiniGEN Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
Ordinary
Ordinary 75,560 $0.000125 $62.51 $62.51 1x $62.51 35.52%
Ordinary 15,834 $0.000125 $31.25 $31.25 1x $31.25 7.44%
To view DefiniGEN’s complete cap table history, request access »

DefiniGEN Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of highly functional human cell products designed to cure liver disease through highly predictive in vitro mod
Biotechnology
Cambridge, United Kingdom
15 As of 2025

Leiden, Netherlands
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

DefiniGEN Competitors (10)

One of DefiniGEN’s 10 competitors is Ncardia, a Venture Capital-Backed company based in Leiden, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ncardia Venture Capital-Backed Leiden, Netherlands
bit.bio Venture Capital-Backed Cambridge, United Kingdom
Newcells Biotech Venture Capital-Backed Newcastle Upon Tyne, United Kingdom
FUJIFILM Cellular Dynamics Formerly VC-backed Madison, WI
Lifeline Cell Technology Corporate Backed or Acquired Frederick, MD
You’re viewing 5 of 10 competitors. Get the full list »

DefiniGEN Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

DefiniGEN Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
24Haymarket Venture Capital Minority
BGF (Financial Services) Growth/Expansion Minority
Cambridge Angels Angel Group Minority
Cambridge Capital Group Angel Group Minority
Cambridge Enterprise Ventures Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Ready to get started?

Request a free trial

DefiniGEN FAQs

  • When was DefiniGEN founded?

    DefiniGEN was founded in 2011.

  • Where is DefiniGEN headquartered?

    DefiniGEN is headquartered in Cambridge, United Kingdom.

  • What is the size of DefiniGEN?

    DefiniGEN has 15 total employees.

  • What industry is DefiniGEN in?

    DefiniGEN’s primary industry is Biotechnology.

  • Is DefiniGEN a private or public company?

    DefiniGEN is a Private company.

  • What is DefiniGEN’s current revenue?

    The current revenue for DefiniGEN is .

  • How much funding has DefiniGEN raised over time?

    DefiniGEN has raised $15.9M.

  • Who are DefiniGEN’s investors?

    24Haymarket, BGF (Financial Services), Cambridge Angels, Cambridge Capital Group, and Cambridge Enterprise Ventures are 5 of 16 investors who have invested in DefiniGEN.

  • Who are DefiniGEN’s competitors?

    Ncardia, bit.bio, Newcells Biotech, FUJIFILM Cellular Dynamics, and Lifeline Cell Technology are some of the 10 competitors of DefiniGEN.

  • When was DefiniGEN acquired?

    DefiniGEN was acquired on 22-Sep-2025.

  • Who acquired DefiniGEN?

    DefiniGEN was acquired by Pixl Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process